Heidi Hermes Shantz, MD
MOHS-Micrographic Surgery · Sequim, WANPI 1932338506
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 32.8% of the total. That places this record below the midpoint for mohs-micrographic surgery clinicians in WA, where the typical reported total is $1,261.
Across 61 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$414
- Novartis$267
- AbbVie$262
- Regeneron Healthcare Solutions, Inc.$95
- Lilly USA, LLC$47
- Organogenesis Inc.$44
- plus $132 from 6 others
What the payments were for
- Food & beverage$1,16292%
- Education$998%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 19 | $414 |
| Novartis | 15 | $267 |
| AbbVie | 12 | $262 |
| Regeneron Healthcare Solutions, Inc. | 3 | $95 |
| Lilly USA, LLC | 3 | $47 |
| Organogenesis Inc. | 2 | $44 |
| UCB, Inc. | 2 | $44 |
| Genentech USA, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Arcutis Biotherapeutics, Inc. | 1 | $20 |
| Sanofi | 1 | $15 |
| Biofrontera Inc. | 1 | $7 |
How this compares
$1,261 in reported general payments places this provider in the 50th percentile of 38 mohs-micrographic surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 33 | $1,659 |
| Gentamicin Sulfate | 30 | $822 |
| Clobetasol Propionate | 33 | $545 |
| Cephalexin | 67 | $487 |
| Mupirocin | 51 | $409 |
| Doxycycline Monohydrate | 14 | $347 |
| Ketoconazole | 23 | $338 |
| Triamcinolone Acetonide | 32 | $258 |
| Doxycycline Hyclate | 19 | $248 |
| Tramadol Hcl | 13 | $25 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Sequim
- Ein Gun SongMill Creek$4.5M
- Jeremy PeckRichland$9K
- Marcus TanRenton$8K
- Mikel MuseVancouver$6K
- Jennifer ReichelSeattle$5K
- Kirk EcklundYakima$5K
- John NiaSpokane$5K
- Mustufa JafryMill Creek$4K
- Maureen MooneyUniversity Place$4K
- Nobuyoshi KageyamaRenton$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.